Oak Ridge, TN, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will present at the H.C. Wainwright 27th Annual Global Investment Conference being held on September 8-10, 2025 in New York City at the Lotte New York Palace Hotel. The presentation will be available on-demand beginning Friday, September 5 at 7:00 a.m. ET. Investors who wish to listen to the Company’s presentatio ...

Sign up to receive news on Daxor's innovative technology HERE. About Daxor Corporation Daxor Corporation (NASDAQ: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor's patented, FDA-cleared Blood Volume Analysis (BVA) ...

The ezBVA Lab service and on-site BVA analyzers utilize Daxor's proprietary technology to deliver gold- standard blood volume measurements, empowering clinicians with actionable diagnostic insights that have been clinically proven to reduce mortality, hospital readmissions and length of stay when managing heart failure and other critical conditions. About Daxor Corporation Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. ...

Daxor's Innovative ezBVA Lab Service Drives Accessibility and Operational Efficiency Oak Ridge, TN, May 06, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces significant expansion of its blood volume analysis (BVA) capabilities in three new hospitals. This growth is accelerated by the widespread adoption of Daxor's ezBVA Lab service – a cutting-edge, CLIA-certified facility delivering precise, on-demand blood volume analysis r ...

Advanced BVA System Designed for Faster, Simpler Bedside Testing Oak Ridge, TN, April 10, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), a leader in blood volume measurement technology, announces today the submission of its next-generation blood volume analyzer - Daxor BVA - to the Food and Drug Administration (FDA.), advancing its mission to optimize healthcare through precise fluid management. The new Daxor BVA device represents a significant leap forward in diagnostic technology, offering direc ...

Core Insights - Daxor Corporation reported a strong financial performance for fiscal 2024, achieving a 116.5% increase in revenue compared to 2023, driven by robust demand for its diagnostic systems [4] - The company has successfully transitioned to cash-flow positive operations in Q1 of 2025, excluding non-cash expenses [4] - Daxor is focused on launching its next-generation blood volume analyzer, which is expected to enhance clinical workflows and open new market opportunities [2] Financial Highlights - The net asset value (NAV) per share increased to $7.25 for fiscal 2024 from $7.08 in 2023 [1] - Daxor signed 12 new accounts in 2024, resulting in a 60.1% growth in the number of diagnostic kits sold year-over-year [4] - The company secured a $2.5 million two-year contract from the Department of Defense, contributing to its commercial momentum [4] Operational Developments - Daxor's next-generation blood volume analyzer is set to be filed for FDA approval via the rapid 510(k) pathway, which will facilitate point-of-care blood volume measurements [2] - The first two months of 2025 saw record-breaking monthly kit revenue, indicating accelerating adoption of Daxor's products [4] - The company received over $350,000 in grants from NIH and Launch Tennessee to support ongoing research and development [4] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, with its BVA-100 being the only FDA-cleared diagnostic blood test for quantifying blood volume status [3] - The company has performed over 65,000 tests at leading hospital centers across the U.S., significantly improving patient outcomes in various medical conditions [3] - Daxor is engaged in ongoing trials for heart failure treatment with support from the NIH and is developing analyzers for combat casualty care with the U.S. Department of Defense [3]